PT - JOURNAL ARTICLE AU - Wolfe, Marlene K. AU - Topol, Aaron AU - Knudson, Alisha AU - Simpson, Adrian AU - White, Bradley AU - Vugia, Duc J. AU - Yu, Alexander T. AU - Li, Linlin AU - Balliet, Michael AU - Stoddard, Pamela AU - Han, George S. AU - Wigginton, Krista R. AU - Boehm, Alexandria B. TI - High frequency, high throughput quantification of SARS-CoV-2 RNA in wastewater settled solids at eight publicly owned treatment works in Northern California shows strong association with COVID-19 incidence AID - 10.1101/2021.07.16.21260627 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.16.21260627 4099 - http://medrxiv.org/content/early/2021/07/20/2021.07.16.21260627.short 4100 - http://medrxiv.org/content/early/2021/07/20/2021.07.16.21260627.full AB - A number of recent retrospective studies have demonstrated that SARS-CoV-2 RNA concentrations in wastewater are associated with COVID-19 cases in the corresponding sewersheds. Implementing high-resolution, prospective efforts across multiple plants depends on sensitive measurements that are representative of COVID-19 cases, scalable for high throughput analysis, and comparable across laboratories. We conducted a prospective study across eight publicly owned treatment works (POTWs). A focus on SARS-CoV-2 RNA in solids enabled us to scale-up our measurements with a commercial lab partner. Samples were collected daily and results were posted to a website within 24-hours. SARS-CoV-2 RNA in daily samples correlated to incidence COVID-19 cases in the sewersheds; a 1 log10 increase in SARS-CoV-2 RNA in settled solids corresponds to a 0.58 log10 (4X) increase in sewershed incidence rate. SARS-CoV-2 RNA signals measured with the commercial laboratory partner were comparable across plants and to measurements conducted in a university laboratory when normalized by pepper mild mottle virus PMMoV RNA. Results suggest that SARS-CoV-2 RNA should be detectable in settled solids for COVID-19 incidence rates > 1/100,000 (range 0.8 - 2.3 cases per 100,000). These sensitive, representative, scalable, and comparable methods will be valuable for future efforts to scale-up wastewater-based epidemiology.Importance Access to reliable, rapid monitoring data is critical to guide response to an infectious disease outbreak. For pathogens that are shed in feces or urine, monitoring wastewater can provide a cost-effective snapshot of transmission in an entire community via a single sample. In order for a method to be useful for ongoing COVID-19 monitoring, it should be sensitive for detection of low concentrations of SARS-CoV-2, representative of incidence rates in the community, scalable to generate data quickly, and comparable across laboratories. This paper presents a method utilizing wastewater solids to meet these goals, producing measurements of SARS-CoV-2 RNA strongly associated with COVID-19 cases in the sewershed of a publicly owned treatment work. Results, provided within 24 hrs, can be used to detect incidence rates as low as approximately 1/100,000 cases and can be normalized for comparison across locations generating data using different methods.Competing Interest StatementAaron Topol, Alisha Knudson, Adrian Simpson, and Bradley White are employed by Verily Life Sciences, and Marlene K Wolfe has provided consulting services for Verily Life Sciences.Clinical Protocols https://www.protocols.io/view/high-throughput-sars-cov-2-pmmov-and-bcov-quantifi-btywnpxe https://www.protocols.io/view/high-throughput-rna-extraction-and-pcr-inhibitor-r-btyrnpv6 https://www.protocols.io/view/high-throughput-pre-analytical-processing-of-waste-btyqnpvw Funding StatementThis work is supported by a gift from the CDC-Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWastewater data used for this analysis are available through the Stanford Digital Repository. https://purl.stanford.edu/bx987vn9177